---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283362156.md"
description: "Passage Bio shares are trading lower after the company announced the FDA did not support a single-arm trial design for its indication in the Type C meeting and instead indicated that a randomized controlled trial would be required for registrational purposes. Also, the company announced it initiated a review of strategic alternatives to maximize shareholder value."
datetime: "2026-04-20T13:02:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283362156.md)
  - [en](https://longbridge.com/en/news/283362156.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283362156.md)
---

# 

Passage Bio shares are trading lower after the company announced the FDA did not support a single-arm trial design for its indication in the Type C meeting and instead indicated that a randomized controlled trial would be required for registrational purposes. Also, the company announced it initiated a review of strategic alternatives to maximize shareholder value.

### Related Stocks

- [PASG.US](https://longbridge.com/en/quote/PASG.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [BioInvent Reveals Solid Data with its TNFR2 Antibody BI-1808 and KEYTRUDA(R) (pembrolizumab) in Advanced Ovarian Cancer at ASCO](https://longbridge.com/en/news/287276384.md)
- [Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline | LIMN Stock News](https://longbridge.com/en/news/287218720.md)
- [Korro Bio To Advance KRRO-111 As Potential Treatment For AATD](https://longbridge.com/en/news/287089978.md)